Last updated: February 18, 2026

Sulfisoxazole acetyl, a sulfonamide antibiotic, has a long history in the pharmaceutical market. Its patent landscape is largely expired, leading to widespread generic availability. The drug's market trajectory is characterized by a mature, price-sensitive environment driven by generic competition and established therapeutic use.

What is the Chemical Composition and Mechanism of Action of Sulfisoxazole Acetyl?

Sulfisoxazole acetyl is a prodrug of sulfisoxazole, a short-acting sulfonamide antibiotic. The chemical formula for sulfisoxazole acetyl is C₁₃H₁₅N₃O₃S₂. It is synthesized by acetylating the amino group of sulfisoxazole. Upon administration, sulfisoxazole acetyl is hydrolyzed in the gastrointestinal tract to release active sulfisoxazole.

Sulfisoxazole inhibits bacterial growth by competitively antagonizing para-aminobenzoic acid (PABA). PABA is an essential precursor for the bacterial synthesis of folic acid, a vitamin crucial for DNA and RNA synthesis. By blocking PABA incorporation, sulfisoxazole effectively halts bacterial proliferation.

What is the History of Sulfisoxazole Acetyl's Patent Protection?

Sulfisoxazole itself was first patented in the mid-20th century. Specific patents covering sulfisoxazole acetyl formulations and manufacturing processes have long since expired. For instance, patents relating to early formulations and synthesis methods would have expired decades ago, given the drug's historical introduction. The absence of active, compound patents means that no single entity holds exclusive rights to the active pharmaceutical ingredient (API). This allows for the production and marketing of generic versions by multiple manufacturers once primary patents lapse.

Who are the Key Manufacturers and Marketers of Sulfisoxazole Acetyl?

The market for sulfisoxazole acetyl is characterized by a significant number of generic manufacturers rather than a few dominant brand-name players. Companies that manufacture and market generic antibiotics, including sulfisoxazole acetyl, operate in a highly competitive space. These companies typically include:

Teva Pharmaceuticals: A major global generic drug manufacturer with a broad portfolio.
Mylan N.V. (now Viatris): Another significant player in the generic pharmaceutical market.
Sandoz (a division of Novartis): A leading global manufacturer of generic and biosimilar medicines.
Amneal Pharmaceuticals: A U.S.-based generic pharmaceutical company.
Various smaller, regional generic manufacturers: These companies often focus on specific markets or niche products.

These manufacturers produce sulfisoxazole acetyl under various generic labels, often competing on price and supply chain efficiency.

What are the Primary Therapeutic Uses and Indications for Sulfisoxazole Acetyl?

Sulfisoxazole acetyl is primarily indicated for the treatment of urinary tract infections (UTIs) caused by susceptible microorganisms. Its spectrum of activity includes many common Gram-negative bacteria responsible for UTIs, such as:

Escherichia coli
Klebsiella spp.
Proteus mirabilis
Proteus vulgaris
Enterobacter spp.

It is also used in the treatment of:

Upper respiratory tract infections: Including sinusitis, bronchitis, and pharyngitis caused by susceptible bacteria.
Middle ear infections (otitis media): When caused by susceptible organisms.
Prophylaxis and treatment of toxoplasmosis: Often in combination with pyrimethamine, particularly in immunocompromised patients.

The drug's efficacy is generally considered good for uncomplicated UTIs, but its use has been impacted by increasing bacterial resistance to sulfonamides and the availability of newer, broader-spectrum antibiotics.

What is the Current Market Size and Projected Growth for Sulfisoxazole Acetyl?

The global market for sulfisoxazole acetyl is a mature, price-sensitive segment of the antibiotic market. Exact market size figures are difficult to isolate for this specific, older drug as it is often grouped within broader antibiotic or sulfonamide categories. However, it is understood to be a relatively small market compared to newer antibiotics.

Market Size: Estimated to be in the tens of millions of U.S. dollars globally. This figure is a qualitative assessment based on its generic status, limited new indications, and competition.
Projected Growth: Minimal to negative growth is anticipated. The market is expected to remain stable or decline slightly due to several factors:
- Bacterial Resistance: Growing resistance of common pathogens to sulfonamides limits its effectiveness.
- Competition: Availability of numerous generic alternatives from multiple manufacturers drives down prices and limits revenue potential.
- Newer Antibiotics: The development and adoption of newer antibiotics with broader spectrums of activity and improved resistance profiles have reduced the reliance on older drugs like sulfisoxazole acetyl for many indications.
- Therapeutic Guidelines: Shifting clinical guidelines may favor other antibiotic classes for certain infections.

The market's stability is largely sustained by its historical use, low manufacturing cost, and continued utility in specific niches, particularly in cost-sensitive healthcare systems or for certain uncomplicated UTIs where resistance is not a significant concern.

What are the Key Factors Driving Demand for Sulfisoxazole Acetyl?

Despite its mature status, several factors continue to drive demand for sulfisoxazole acetyl:

Cost-Effectiveness: As a generic drug produced by multiple manufacturers, sulfisoxazole acetyl is highly cost-effective. This makes it an attractive option in resource-limited settings or for healthcare systems prioritizing cost containment.
Established Efficacy for Specific Infections: For certain uncomplicated urinary tract infections and specific respiratory tract infections caused by known susceptible organisms, sulfisoxazole acetyl remains an effective and well-understood treatment option.
Availability and Accessibility: Its widespread generic availability ensures that it is readily accessible to patients and healthcare providers.
Pediatric Use: Historically, it has been used in pediatric populations, although this use may be declining with the advent of more palatable formulations of other antibiotics.
Alternative for Penicillin Allergy: In patients with penicillin allergies, sulfonamides can serve as an alternative, though cross-reactivity with other antibiotic classes must be considered.
Specific Niche Indications: Its role in the management of toxoplasmosis in combination therapy sustains a specific demand.

What are the Primary Challenges and Risks Associated with Sulfisoxazole Acetyl?

The market for sulfisoxazole acetyl faces significant challenges:

Bacterial Resistance: This is the most critical challenge. Increasing rates of resistance among common UTI pathogens, such as E. coli, to sulfonamides limit the drug's empirical use and necessitate susceptibility testing.
Adverse Drug Reactions: Sulfonamides can cause a range of adverse effects, including hypersensitivity reactions, crystalluria (requiring adequate hydration), and potential for Stevens-Johnson syndrome in rare cases.
Drug Interactions: Sulfisoxazole can interact with other medications, including warfarin (increasing anticoagulant effect) and methotrexate (increasing toxicity).
Competition from Newer Antibiotics: The market is saturated with newer antibiotics that offer broader-spectrum coverage, better safety profiles, or improved resistance patterns, leading to a gradual shift away from older drugs.
Formulation Limitations: Older formulations might be less palatable or convenient compared to newer drug delivery systems.
Regulatory Scrutiny: As with all antibiotics, there is ongoing regulatory scrutiny regarding antibiotic stewardship and the development of resistance, which can impact prescribing patterns.
Limited Pipeline Innovation: There is little to no significant research and development investment in new formulations or expanded indications for sulfisoxazole acetyl, as the market is primarily generic.

What is the Regulatory Landscape for Sulfisoxazole Acetyl?

Sulfisoxazole acetyl is approved for marketing by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its regulatory status is primarily that of an established generic drug. Key aspects of its regulatory landscape include:

Abbreviated New Drug Application (ANDA) Pathway: Generic manufacturers seeking to market sulfisoxazole acetyl must demonstrate bioequivalence to a reference listed drug through the ANDA process in the U.S.
Good Manufacturing Practices (GMP): All manufacturers must adhere to strict GMP guidelines to ensure product quality, safety, and efficacy.
Pharmacovigilance: Post-market surveillance for adverse events is required, as with all approved drugs.
Labeling Requirements: Prescribing information must accurately reflect indications, contraindications, warnings, precautions, and adverse reactions, based on established data and evolving scientific understanding.
Antibiotic Stewardship: Regulatory bodies and public health organizations promote antibiotic stewardship programs, which may influence prescribing practices for older antibiotics like sulfisoxazole acetyl, encouraging their use only when appropriate and based on susceptibility data.

What is the Competitive Landscape for Sulfisoxazole Acetyl?

The competitive landscape for sulfisoxazole acetyl is characterized by intense generic competition.

Numerous Generic Manufacturers: A substantial number of pharmaceutical companies produce and market generic versions of sulfisoxazole acetyl. This leads to a fragmented market with many suppliers.
Price-Based Competition: The primary competitive differentiator among generic manufacturers is price. Companies with efficient manufacturing processes and robust supply chains can offer lower prices, gaining market share.
Established Supply Chains: The drug has been on the market for a long time, meaning established manufacturing and distribution channels are in place.
Limited Brand Differentiation: With the loss of patent exclusivity, brand name recognition is minimal. Prescribers and pharmacists primarily rely on cost and availability when selecting a generic product.
Competition from Alternative Antibiotics: Beyond direct generic competition, sulfisoxazole acetyl competes with a vast array of other antibiotic classes, including fluoroquinolones, cephalosporins, and macrolides, which may be preferred due to broader coverage or perceived efficacy.

This environment suggests that opportunities for significant market expansion or profit maximization are limited for individual sulfisoxazole acetyl products. Success relies on high-volume sales at low margins.

What are the Financial Implications and Investment Outlook for Sulfisoxazole Acetyl?

The financial implications and investment outlook for sulfisoxazole acetyl are largely unfavorable for new entrants or significant R&D investment, given its market characteristics.

Low Profit Margins: Due to intense price competition and the generic nature of the product, profit margins are typically low.
High Volume, Low Margin Strategy: Manufacturers generate revenue through high-volume sales rather than premium pricing.
Mature Market Dynamics: The market has reached saturation, with minimal potential for significant growth. Revenue streams are stable but not expanding.
Limited R&D Investment: There is little incentive for substantial investment in new clinical trials, drug discovery, or novel formulations for sulfisoxazole acetyl. Focus is on efficient, cost-effective production of existing formulations.
Acquisition Target Considerations: For larger pharmaceutical companies, acquiring a portfolio of established generics like sulfisoxazole acetyl might be part of a broader strategy to maintain market share and revenue from established products, rather than a growth driver.
Investment Risk: Investing in the development or manufacturing of sulfisoxazole acetyl carries risks related to pricing pressures, potential for increased generic competition, and the ongoing threat of antibiotic resistance impacting its utility.

The financial trajectory is one of steady, albeit low, revenue generation for established generic producers, with little prospect for significant capital appreciation or return on investment beyond operational efficiency.

What is the Outlook for Sulfisoxazole Acetyl in the Next 5-10 Years?

The outlook for sulfisoxazole acetyl over the next 5-10 years is stable but characterized by continued market maturity and potential decline.

Sustained Generic Availability: The drug will remain widely available as a generic due to its established manufacturing processes and continued, albeit limited, therapeutic use.
Continued Pressure from Resistance: The growing challenge of bacterial resistance is likely to further restrict its use, particularly for empirical treatment of UTIs. Prescribing will increasingly rely on susceptibility testing.
Competition from Newer Antibiotics: Newer, more effective, and broader-spectrum antibiotics will continue to capture market share for many indications.
Price Erosion: Ongoing generic competition will likely lead to further, albeit gradual, price erosion.
Niche Market Persistence: Sulfisoxazole acetyl will likely retain its niche in specific, uncomplicated infections where it remains effective and cost-advantageous, and in certain off-label or combination therapies (e.g., toxoplasmosis).
Limited Innovation: No significant pipeline developments or new indications are anticipated.

The drug's role will likely diminish further as a frontline treatment but persist as a cost-effective option in specific, well-defined scenarios where its limitations are understood and managed.

Key Takeaways

Sulfisoxazole acetyl is a mature, generic antibiotic with no active compound patents. Its market is characterized by intense price-based competition among numerous manufacturers, leading to low profit margins. While still used for urinary tract infections and other niche indications, its utility is increasingly constrained by rising bacterial resistance and the availability of newer, broader-spectrum antibiotics. The market is projected to remain stable with minimal to negative growth. Investment focus is on operational efficiency and high-volume sales rather than growth opportunities. Regulatory oversight primarily pertains to manufacturing quality and post-market surveillance, with no significant pipeline innovation expected.

Frequently Asked Questions

1. Will new patents for sulfisoxazole acetyl formulations emerge?

It is highly unlikely that significant new patents for sulfisoxazole acetyl formulations will emerge or be commercially viable. The drug is well-established, and any novel formulations would need to demonstrate substantial improvements in efficacy, safety, or patient compliance to justify the patenting and development costs in a market dominated by low-cost generics.

2. How does bacterial resistance specifically impact sulfisoxazole acetyl's market share?

Bacterial resistance directly erodes sulfisoxazole acetyl's market share by reducing its efficacy as a first-line treatment. As common pathogens like E. coli develop resistance, prescribers are compelled to use other antibiotics, necessitating susceptibility testing for sulfisoxazole acetyl and limiting its empirical use. This forces a shift towards agents with broader or more reliable coverage.

3. Are there any specific geographical markets where sulfisoxazole acetyl remains more dominant?

Sulfisoxazole acetyl may retain a relatively stronger position in developing countries or specific emerging markets where cost is a primary determinant of drug selection and access to newer, more expensive antibiotics is limited. These regions might exhibit slower adoption of newer therapies and a greater reliance on established, cost-effective generics.

4. What are the primary safety concerns for patients using sulfisoxazole acetyl today?

Primary safety concerns include potential hypersensitivity reactions (including severe skin reactions), crystalluria (requiring adequate fluid intake), and drug interactions, particularly with anticoagulants like warfarin. The risk of Stevens-Johnson syndrome, though rare, remains a serious consideration for sulfonamides.

5. Can sulfisoxazole acetyl be repurposed for new therapeutic areas?

Repurposing sulfisoxazole acetyl for new therapeutic areas is improbable. The current scientific and clinical landscape favors the development of novel molecules or advanced drug platforms for new indications. Existing data and the drug's mechanism of action do not strongly suggest potential in areas beyond its established antimicrobial role, especially given the focus on antimicrobial resistance.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Generic Drugs Program. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drug-program

[2] World Health Organization. (2020). Antibiotic resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance

[3] Patel, N., & Sharma, S. (2018). Sulfonamides. In StatPearls. StatPearls Publishing.

[4] Lexicomp. (n.d.). Sulfisoxazole Acetyl. Retrieved from [Lexicomp Database] (Access required)

[5] European Medicines Agency. (n.d.). Authorisation of medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory-information/medicines/authorisation-medicines

US Patents:	0
Tradenames:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	50
DailyMed Link:	sulfisoxazole acetyl at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	GANTRISIN	sulfisoxazole acetyl	SYRUP;ORAL	009182-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Roche	GANTRISIN PEDIATRIC	sulfisoxazole acetyl	SUSPENSION;ORAL	009182-004	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Roche	LIPO GANTRISIN	sulfisoxazole acetyl	EMULSION;ORAL	009182-009	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Sulfisoxazole acetyl - Generic Drug Details

What are the generic sources for sulfisoxazole acetyl and what is the scope of patent protection?

Summary for sulfisoxazole acetyl

US Patents and Regulatory Information for sulfisoxazole acetyl

Sulfisoxazole Acetyl: Patent Expirations and Market Trajectory